Suspicions are confirmed: Pharma's spending on ads took a flying leap last year. By Kantar Media's numbers, direct-to-consumer ad spend hit $4.53 billion in 2014, up about 18% from $3.83 billion in 2013.
For some industry watchers, AbbVie's $21 billion pact to buy Imbruvica-maker Pharmacyclics begged a lot of questions. For instance, after the company agreed to pay a price that steep--or "lofty," "staggering," and even "astronomical," to use analysts' words--how much would Imbruvica actually rack up in peak sales? And where would those sales come from?
What's better than a new drug launch? A launch destined for greatness, of course. For sales and marketing teams, that's about as much job security as you can get.
A couple of geriatrics experts have joined the chorus of recommendations against testosterone therapy. But they're going a step further. They say drugmakers' enthusiastic advertising--which happened to be effective, too--was actually disease-mongering.
Sanofi is hoping to spring forward with a new marketing campaign for OTC Nasacort.
Newcomers showed off at this year's American Academy of Dermatology meeting, with more than one touting Stelara-beating data--and prepping the market for an all-out psoriasis war.
Any opinions about which new direct-to-consumer TV ads worked best last year? Check yours against the top 10 curated by Medical Marketing & Media.
Anyone who follows the pharma industry knows just how much cancer drug prices have increased as of late--Mayo Clinic oncologists among them. And they've got their own ideas on how to turn that around, though they're not necessarily ideas pharma would favor.